Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of VX-548 in Renal Impairment
NCT05704556Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of suzetrigine in acute pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of VX-548 and its Metabolite and Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity. Started Feb 2023; status: completed.
02
Drugs
suzetrigine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT05704556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704556.